Posted by Michael Wonder on 24 Apr 2018
Institute for Clinical and Economic Review to assess biologic treatments for asthma in upcoming assessment
24 April 2018 - Report will be subject of November Midwest CEPAC meeting; open input now being accepted until 10 May.
The Institute for Clinical and Economic Review (ICER) today announced plans to develop a review assessing the comparative clinical effectiveness and value of biologic therapies for moderate-to-severe asthma. The report is set to be reviewed during a November 2018 public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), one of ICER's three independent evidence appraisal committees.
ICER's report is expected to include five therapies: dupilumab (Dupixent, Sanofi/Regeneron), omalizumab (Xolair, Genentech/Novartis), mepolizumab (Nucala, GlaxoSmithKline), reslizumab (Cinqair, Teva), and benralizumab (Fasenra, AstraZeneca). ICER previously reviewed mepolizumab for its use in severe eosinophilic asthma and dupilumab for its use in atopic dermatitis. Dupilumab is currently under FDA review for use as add-on maintenance treatment in moderate-to-severe asthma, with an approval decision expected in October of 2018.
